Targeting Mutant BRAF with Vemurafenib in Relapsed or Refractory Hairy Cell Leukemia

BACKGROUND: BRAF-V600E is the genetic lesion underlying hairy cell leukemia. We assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy cell leukemia who relapsed after or were refractory to purine analogues. METHODS: We conducted in Italy and USA two phase-2 s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:N Engl J Med
Autors principals: Tiacci, Enrico, Park, Jae H., De Carolis, Luca, Chung, Stephen S., Broccoli, Alessandro, Scott, Sasinya, Zaja, Francesco, Devlin, Sean, Pulsoni, Alessandro, Chung, Young Rock, Cimminiello, Michele, Kim, Eunhee, Rossi, Davide, Stone, Richard M., Motta, Giovanna, Saven, Alan, Varettoni, Marzia, Altman, Jessica K., Anastasia, Antonella, Grever, Michael R., Ambrosetti, Achille, Rai, Kanti R., Fraticelli, Vincenzo, Lacouture, Mario E., Carella, Angelo Michele, Levine, Ross L., Leoni, Pietro, Rambaldi, Alessandro, Falzetti, Franca, Ascani, Stefano, Capponi, Monia, Martelli, Maria Paola, Park, Christopher Y., Pileri, Stefano Aldo, Rosen, Neal, Foà, Robin, Berger, Michael F., Zinzani, Pier Luigi, Abdel-Wahab, Omar, Falini, Brunangelo, Tallman, Martin S.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4811324/
https://ncbi.nlm.nih.gov/pubmed/26352686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1506583
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars